Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schenk

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Frontiers in Oncology|March 7, 2022
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI TrialAnnika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
International Journal of Cancer|March 8, 2023
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIMThorsten O Goetze, Ralf-Dieter Hofheinz, Timo Gaiser, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh<sup>®TM</sup>) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic CancerKlara Dorman, Stefan Boeck, Robert J Snijder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 TrialSylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Haematologica|December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IVChristian Michel, Andreas Burchert, Andreas Hochhaus, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Frontiers in Oncology|March 7, 2022
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI TrialAnnika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
International Journal of Cancer|March 8, 2023
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIMThorsten O Goetze, Ralf-Dieter Hofheinz, Timo Gaiser, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh<sup>®TM</sup>) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic CancerKlara Dorman, Stefan Boeck, Robert J Snijder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 TrialSylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Haematologica|December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IVChristian Michel, Andreas Burchert, Andreas Hochhaus, et al.
Pageof 6